Independent Assurance Report

To the President and CEO of Astellas Pharma Inc.

We were engaged by Astellas Pharma Inc. (the "Company") to undertake a limited assurance engagement of the environmental performance indicators marked with [ ] for the period from April 1, 2020 to March 31, 2021 (the "EPIs") and the social performance indicators marked with [ ] for the period from January 1, 2020 to December 31, 2020 (the "SPIs") included in the Company’s websites found under www.astellas.com/en/sustainability and www.astellas.com/jp/en/sustainability (the "Websites"). (The EPIs for overseas sites include only energy use, greenhouse gas emissions, water use and waste generated for the period from January 1, 2020 to December 31, 2020.)

The Company’s Responsibility
The Company is responsible for the preparation of the EPIs and SPIs in accordance with its own reporting criteria (the “Company’s reporting criteria”), as described in the Websites.

Our Responsibility
Our responsibility is to express a limited assurance conclusion on the EPIs and SPIs based on the procedures we have performed. We conducted our engagement in accordance with the ‘International Standard on Assurance Engagements (ISAE) 3000, Assurance Engagements other than Audits or Reviews of Historical Financial Information’ and the ‘ISAE 3410, Assurance Engagements on Greenhouse Gas Statements’ issued by the International Auditing and Assurance Standards Board. The limited assurance engagement consisted of making inquiries, primarily of persons responsible for the preparation of information presented in the Websites, and applying analytical and other procedures, and the procedures performed vary in nature from, and are less in extent than for, a reasonable assurance engagement. The level of assurance provided is thus not as high as that provided by a reasonable assurance engagement. Our assurance procedures included:

- Interviewing the Company’s responsible personnel to obtain an understanding of its policy for preparing the Websites and reviewing the Company’s reporting criteria.
- Making inquiries and reviewing materials including documented evidence of Astellas Pharma Tech Co., Ltd.’s Takaoka Plant selected on the basis of a risk analysis, as alternative procedures to a site visit.
- Performing analytical procedures on the EPIs and SPIs.
- Examining, on a test basis, evidence supporting the generation, aggregation and reporting of the EPIs and SPIs in conformity with the Company’s reporting criteria, and recalculating the EPIs and SPIs.
- Evaluating the overall presentation of the EPIs and SPIs.

Conclusion
Based on the procedures performed, as described above, nothing has come to our attention that causes us to believe that the EPIs and SPIs in the Websites are not prepared, in all material respects, in accordance with the Company’s reporting criteria as described in the Websites.

Our Independence and Quality Control
We have complied with the Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants, which includes independence and other requirements founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior. In accordance with International Standard on Quality Control 1, we maintain a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

KPMG AZSA Sustainability Co., Ltd.
Tokyo, Japan
June 25, 2021